|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Apatinib:a promising oral antiangiogenic agent in the treatment of multiple solid tumors显示文摘 | Scott AJ Messersmith WA Jimeno A | 2015 | Drugs Today(Barc)2015，51，4： | 1 |
| 2 | Phase I study of Rigosertib,an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways,combined with gemcitabine in patients with solid tumors and pancreatic cancer显示文摘 | Ma WW Messersmith WA Dy GK | | 0，，08： | 1 |
| 3 | Effi- cacy and pharmacodynamic effects of bosutinib ( SKI-606 ) , a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts显示文摘 | MESSERSMITH WA RAJESHKUMAR NV TAN AC | 2009 | Mol Cancer Ther2009，8，6： | 1 |
| 4 | Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts显示文摘 | MESSERSMITH WA RAJESHKUMAR NV TAN AC | 2009 | Mol Cancer Ther2009，8，6： | 1 |
| 5 | Bosutinib (SKI- 606), a dual Src/Abl tyrosine kinase inhibitor: Preliminary results from a phase 1 study in patients with advanced malignant solid tumors显示文摘 | MESSERSMITH WA KRISHNAMURTHI S HEWES BA et a/ | | J Clin Oncol0，25，18： | 1 |
| 6 | Phase I study of RO4929097,a gamma secretase inhibitor of Notch signaling,in patients with refractory metastatic or locally advanced solid tumors显示文摘 | Tolcher AW Messersmith WA Mikulski SM | 2012 | J Clin Oncol2012，30，19： | 1 |
| 7 | Novel agents in the treatment of metastatic colorectal cancer 显示文摘 | Leong S Messersmith WA Tan AC | 2010 | CancerJ2010，16，3： | 1 |
| 8 | Phase I study of RO4929097, a gamma secretase inhibitor of Notch signalinl, in patients with refractory metastatic or locally advanced solid tumors显示文摘 | Tolcher AW Messersmith WA Mikulski SM | 2012 | J Clin Oncol2012，30，19： | 1 |
| 9 | A phase Ⅰ study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal carcinoma and non-small cell lung cancer显示文摘 | Dasari A Gore L Messersmith WA | 2012 | Invest New Drugs2012，31，1： | 1 |
| 10 | The development of regorafenib and its current and potential fu- ture role in cancer therapy显示文摘 | DAVIS SL ECKHARDT SG MESSERSMITH WA | 2013 | Drugs Today (Barc)2013，49，2： | 1 |
| 11 | Phase I study of Rigosertib, an inhibitor of the phosphatidylino- sitol 3-kinase and Polo-like kinase 1 pathways, com- bined with gemcitabine in patients with solid tumors and pancreatic cancer显示文摘 | Ma WW Messersmith WA Dy GK | 2012 | Clin Cancer Res2012，18，7： | 1 |
| 12 | PhaseⅠ trial of irinotecan,infusional 5-fluorouracil,and leucovorin(FOLFIRI)with erlotinib:early termination due to increased toxicity显示文摘 | Messersmith WA Laheru DA Senzer NN | 2004 | Clin Cancer Res2004，10，19： | 1 |
| 13 | Targeting EGFR in colorectal cancer显示文摘 | Messersmith WA | 2008 | N Engl J Med2008，359，17： | 1 |
| 14 | Targeting EGFR in colorectal cancer显示文摘 | Messersmith WA Ahnen DJ | 2008 | N Engl J Med2008，359，17： | 1 |
| 15 | Targeting EGFR in colorectal cancer显示文摘 | Messersmith WA Ahnen DJ | 2008 | N Engl J Med2008，359，17： | 1 |
| 16 | Targeting EGFR in colorectal cancer 显示文摘 | Messersmith WA Ahnen DJ | 2008 | N Engl J Med2008，359，17： | 1 |
| 17 | Targeting EGFR in colectal cancer显示文摘 | Messersmith WA Ahnen DJ | 2008 | N Engl J Med2008，359，17： | 1 |
| 18 | The development of regorafenib and its current and potential future role in cancer therapy显示文摘 | Davis SL Eckhardt SG Messersmith WA | 2013 | Drugs Today (Bare)2013，49，2： | 1 |
| 19 | A phase 1B study of dulanermin in combination with modified FOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer 显示文摘 | Wainberg ZA Messersmith WA Peddi PF | 2013 | Clinical Colorectal Cancer2013，12，4： | 1 |
| 20 | Thedevelopment of regorafenib and its current and potential futurerole in cancer therapy 显示文摘 | DAVIS SL ECKHARDT SG MESSERSMITH WA | 2013 | Drugs Today ( Bare)2013，49，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员